---
title: ""
---

### In trial, prioritised, and non-prioritsed interventions

<br />

#### In trial



::: {.callout-tip icon="false" collapse="true"}
## Baricitinib

First reviewed: April 2023     In trial: tbc

Baricitinib selectively and reversibly inhibits the Janus-associated tyrosine kinases JAK1 and JAK2.
:::

::: {.callout-tip icon="false" collapse="true"}
## Simvaststain

First reviewed: April 2023     In trial: tbc

Simvastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis.
:::

<br />

#### Prioritised

::: {.callout-caution icon="false" collapse="true"}
## Atibuclimab

First reviewed: April 2023     Priority: 1

Atibuclimab (IC14) is a chimeric CD14 antibody
:::

::: {.callout-caution icon="false" collapse="true"}
## IL-6 receptor inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

-    Tocilizumab
:::

::: {.callout-caution icon="false" collapse="true"}
## Complement inhibitors

First reviewed: April 2023     Priority: 1

Specific drugs prioritised to date:

-    Vilobelimab (a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma)
:::

<br />

Where there are multiple drugs in a class, the class is prioritised until the capacity exists for entry into the platform. At this point, a further exercise is undertaken to decide on the specific drug to be taken forward.

<br />

#### Under review

::: {.callout-note icon="false" collapse="true"}
## Artesunate

First reviewed: August 2023

Insufficient evidence at this time.
:::

::: {.callout-note icon="false" collapse="true"}
## CRAC channel inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Specific drugs considered to date:

-    Auxora (CM4620)
:::

::: {.callout-note icon="false" collapse="true"}
## Furosemide

*nebulised/inhaled*

First reviewed: April 2023

Insufficient evidence at this time.
:::

::: {.callout-note icon="false" collapse="true"}
## Galectin-3 inhibitors

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

-    Belapectin (*nebulised/inhaled*)
:::

::: {.callout-note icon="false" collapse="true"}
## Macrolides

First reviewed: April 2023

Insufficient evidence at this time.
:::

::: {.callout-note icon="false" collapse="true"}
## p38 MAPK inhibitors

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

-    Dilmapimod
:::

::: {.callout-note icon="false" collapse="true"}
## PSCK9 inhibitors

First reviewed: August 2023

Insufficient evidence at this time.
:::
 
::: {.callout-note icon="false" collapse="true"}
## Neutrophil elastase inhibitors

First reviewed: August 2023

Insufficient evidence at this time.

Specific drugs considered to date:

-    Sivelestat
:::

::: {.callout-note icon="false" collapse="true"}
## Sphingosine 1-phosphate receptor modulators

First reviewed: April 2023

Insufficient evidence at this time.

Specific drugs considered to date:

-    Fingolimod 
:::

::: {.callout-note icon="false" collapse="true"}
## Tyrosine kinase inhibitors

Reviewed: 24-04-2023

Insufficient evidence at this time.

Specific drugs considered to date:

-    Imatinib.
:::

<br />

#### Not prioritised

::: {.callout-important icon="false" collapse="true"}
## Aspirin

Reviewed: 24-04-2023

Not prioritised on the basis of prevalence of use in the target population.
:::

::: {.callout-important icon="false" collapse="true"}
## Citrulline

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.
:::

::: {.callout-important icon="false" collapse="true"}
## Corticosteroids

Reviewed: 24-04-2023

Not prioritised on the basis of ongoing or proposed trials.
:::

::: {.callout-important icon="false" collapse="true"}
## N-acetyl-cysteine

*nebulised/inhaled*

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.
:::

::: {.callout-important icon="false" collapse="true"}
## Streptokinase

*nebulised/inhaled*

Reviewed: 24-04-2023

Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.
:::
